Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting
Introduction: A literature review was undertaken to identify clinical trials and real-world studies of patients with stage IV NSCLC who had progressed on or after treatment with platinum-based chemotherapy. Methods: The EMBASE and MEDLINE databases were used to search for English-language studies pu...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364323001224 |
| _version_ | 1797454534160678912 |
|---|---|
| author | Yu Yang Soon, MBBS Wesley Furnback, BA Jin Kim, MS Po-Ya Chuang, MHA Gordon Chavez, BA Christina Proescholdt, MD Cloe Ying Chee Koh, MS |
| author_facet | Yu Yang Soon, MBBS Wesley Furnback, BA Jin Kim, MS Po-Ya Chuang, MHA Gordon Chavez, BA Christina Proescholdt, MD Cloe Ying Chee Koh, MS |
| author_sort | Yu Yang Soon, MBBS |
| collection | DOAJ |
| description | Introduction: A literature review was undertaken to identify clinical trials and real-world studies of patients with stage IV NSCLC who had progressed on or after treatment with platinum-based chemotherapy. Methods: The EMBASE and MEDLINE databases were used to search for English-language studies published between September 28, 2017, and September 28, 2021. Studies were included in the review if they (1) were clinical trials or real-world analyses of one or more treatment regimens for patients with stage IV NSCLC who had progressed on or after treatment with platinum-based chemotherapy, (2) contained an end point including efficacy, effectiveness, or safety, and (3) included 45 or more patients. Results: In total, there were 15 publications (nine unique trials and three real-world studies) included. Sample size ranged from 49 to 1253 patients. At least one treatment arm in eight of the nine clinical trials reported an overall response rate of ≥15%. Median progression-free survival (PFS) and overall survival ranged from 1.9 to 5.2 months and 5.4 to 15.4 months in clinical trials and 4.4 to 6.8 months and 8.3 to 18.0 months in real-world studies, respectively. Within studies reporting median PFS, a median PFS of more than or equal to 3 months was reported in eight of 11 clinical trials and both real-world studies. Discontinuation due to adverse events ranged from 1.9% to 18% across all included studies. Conclusions: Patients with stage IV NSCLC had limited response and a high burden of adverse events during treatment after progression on platinum-containing chemotherapy. There remains a pressing unmet need for additional, effective, and tolerable treatment options in this setting. |
| first_indexed | 2024-03-09T15:38:36Z |
| format | Article |
| id | doaj.art-0aeb688d78e54edfb9759f96abdb7994 |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-03-09T15:38:36Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-0aeb688d78e54edfb9759f96abdb79942023-11-25T04:50:21ZengElsevierJTO Clinical and Research Reports2666-36432023-11-01411100579Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure SettingYu Yang Soon, MBBS0Wesley Furnback, BA1Jin Kim, MS2Po-Ya Chuang, MHA3Gordon Chavez, BA4Christina Proescholdt, MD5Cloe Ying Chee Koh, MS6Department of Radiation Oncology, National University Cancer Institute Singapore, Singapore; Novocure, Root, Switzerland; Real Chemistry, Inc., New York, New York; Novocure, Inc., New York, New YorkDepartment of Radiation Oncology, National University Cancer Institute Singapore, Singapore; Novocure, Root, Switzerland; Real Chemistry, Inc., New York, New York; Novocure, Inc., New York, New YorkDepartment of Radiation Oncology, National University Cancer Institute Singapore, Singapore; Novocure, Root, Switzerland; Real Chemistry, Inc., New York, New York; Novocure, Inc., New York, New YorkDepartment of Radiation Oncology, National University Cancer Institute Singapore, Singapore; Novocure, Root, Switzerland; Real Chemistry, Inc., New York, New York; Novocure, Inc., New York, New YorkDepartment of Radiation Oncology, National University Cancer Institute Singapore, Singapore; Novocure, Root, Switzerland; Real Chemistry, Inc., New York, New York; Novocure, Inc., New York, New YorkDepartment of Radiation Oncology, National University Cancer Institute Singapore, Singapore; Novocure, Root, Switzerland; Real Chemistry, Inc., New York, New York; Novocure, Inc., New York, New YorkCorresponding author. Address for correspondence: Cloe Ying Chee Koh, MS, Novocure, Inc., 17th Floor, 1500 Broadway, New York, NY 10036.; Department of Radiation Oncology, National University Cancer Institute Singapore, Singapore; Novocure, Root, Switzerland; Real Chemistry, Inc., New York, New York; Novocure, Inc., New York, New YorkIntroduction: A literature review was undertaken to identify clinical trials and real-world studies of patients with stage IV NSCLC who had progressed on or after treatment with platinum-based chemotherapy. Methods: The EMBASE and MEDLINE databases were used to search for English-language studies published between September 28, 2017, and September 28, 2021. Studies were included in the review if they (1) were clinical trials or real-world analyses of one or more treatment regimens for patients with stage IV NSCLC who had progressed on or after treatment with platinum-based chemotherapy, (2) contained an end point including efficacy, effectiveness, or safety, and (3) included 45 or more patients. Results: In total, there were 15 publications (nine unique trials and three real-world studies) included. Sample size ranged from 49 to 1253 patients. At least one treatment arm in eight of the nine clinical trials reported an overall response rate of ≥15%. Median progression-free survival (PFS) and overall survival ranged from 1.9 to 5.2 months and 5.4 to 15.4 months in clinical trials and 4.4 to 6.8 months and 8.3 to 18.0 months in real-world studies, respectively. Within studies reporting median PFS, a median PFS of more than or equal to 3 months was reported in eight of 11 clinical trials and both real-world studies. Discontinuation due to adverse events ranged from 1.9% to 18% across all included studies. Conclusions: Patients with stage IV NSCLC had limited response and a high burden of adverse events during treatment after progression on platinum-containing chemotherapy. There remains a pressing unmet need for additional, effective, and tolerable treatment options in this setting.http://www.sciencedirect.com/science/article/pii/S2666364323001224NSCLCLiterature reviewResponseReal-world evidence |
| spellingShingle | Yu Yang Soon, MBBS Wesley Furnback, BA Jin Kim, MS Po-Ya Chuang, MHA Gordon Chavez, BA Christina Proescholdt, MD Cloe Ying Chee Koh, MS Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting JTO Clinical and Research Reports NSCLC Literature review Response Real-world evidence |
| title | Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting |
| title_full | Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting |
| title_fullStr | Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting |
| title_full_unstemmed | Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting |
| title_short | Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting |
| title_sort | clinical trial and real world outcomes of patients with metastatic nsclc in the post platinum based chemotherapy failure setting |
| topic | NSCLC Literature review Response Real-world evidence |
| url | http://www.sciencedirect.com/science/article/pii/S2666364323001224 |
| work_keys_str_mv | AT yuyangsoonmbbs clinicaltrialandrealworldoutcomesofpatientswithmetastaticnsclcinthepostplatinumbasedchemotherapyfailuresetting AT wesleyfurnbackba clinicaltrialandrealworldoutcomesofpatientswithmetastaticnsclcinthepostplatinumbasedchemotherapyfailuresetting AT jinkimms clinicaltrialandrealworldoutcomesofpatientswithmetastaticnsclcinthepostplatinumbasedchemotherapyfailuresetting AT poyachuangmha clinicaltrialandrealworldoutcomesofpatientswithmetastaticnsclcinthepostplatinumbasedchemotherapyfailuresetting AT gordonchavezba clinicaltrialandrealworldoutcomesofpatientswithmetastaticnsclcinthepostplatinumbasedchemotherapyfailuresetting AT christinaproescholdtmd clinicaltrialandrealworldoutcomesofpatientswithmetastaticnsclcinthepostplatinumbasedchemotherapyfailuresetting AT cloeyingcheekohms clinicaltrialandrealworldoutcomesofpatientswithmetastaticnsclcinthepostplatinumbasedchemotherapyfailuresetting |